News | November 30, 2022
Gland Pharma to buy French pharma company Cenexi
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
40,000 visitors and representatives of more than 80 countries set to visit the show
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Subscribe To Our Newsletter & Stay Updated
